Panc02 Cells — A Syngeneic Murine Model for Pancreatic Ductal Adenocarcinoma Research

Introduction

The Panc02 Cells line — also known as Panc-02, Panc 02, Pan02, Pan-02, PAN 02, and Panc02-H0 — is a murine pancreatic ductal adenocarcinoma (PDAC) cell line established from a chemically induced tumor in C57BL/6 mice. Corbett and colleagues first described its establishment in 1984, deriving it from a ductal adenocarcinoma that arose after implantation of 3-methylcholanthrene-laden cotton thread into pancreatic tissue. [1] Since then, Panc02 has become one of the most widely employed syngeneic murine models for studying pancreatic neoplasms and carcinoma of the pancreatic ductal type. Its compatibility with the fully immunocompetent C57BL/6 background makes it indispensable for tumor microenvironment studies, immuno-oncology research, and the preclinical evaluation of novel therapeutics — including chemotherapy combinations, nanoparticle drug delivery systems, and immunotherapy strategies targeting the gastrointestinal microbiome.

Key Takeaways

• Panc02 (CVCL_D627) is a murine PDAC cell line derived from chemically induced pancreatic tumors in C57BL/6 mice, first established in 1984.
• Its syngeneic C57BL/6 background enables fully immunocompetent in vivo experiments, preserving native tumor–immune interactions.
• Panc02 is widely used for orthotopic implantation models that recapitulate the pancreatic tumor microenvironment.
• The cell line serves as a robust platform for evaluating chemotherapy resistance, novel drug delivery systems, and immunotherapy strategies.
• Panc02 has a population doubling time of approximately 61 hours and grows as an adherent culture.
• Numerous engineered derivatives and reporter lines (e.g., luciferase-expressing variants) have been generated from Panc02 for specialised research applications.

What is Panc02?

Panc02 is a murine pancreatic ductal adenocarcinoma cell line of C57BL/6 origin (Cellosaurus accession CVCL_D627). It was derived from the pancreatic tissue of a male donor mouse following carcinogen-induced tumorigenesis. The cell line belongs to the cancer cell line category and was established from pancreatic ductal tissue, recapitulating the histological features of pancreatic ductal adenocarcinoma. Genomic analyses have confirmed that Panc02 harbours mutations relevant to PDAC biology, providing a genetically defined background for mechanistic studies. [2] No donor age data are recorded in the Cellosaurus entry.

Comparative characterisation has confirmed that Panc02 displays an irregular, finger-like growth pattern in orthotopic implantation models, with local invasiveness and histological features representative of pancreatic adenocarcinoma. [3] The cell line has a population doubling time of approximately 61 hours. Its syngeneic compatibility with C57BL/6 mice — one of the most widely used inbred strains — makes it particularly valuable for immunologically intact preclinical models. Serial in vivo passaging of Panc02 has produced progressively more aggressive derivatives, the most established of which is Panc02-H7, demonstrating the model's capacity to study tumour evolution and metastatic progression. [4]

Cell Culture Information

Panc02 – low confluency

Panc02 – high confluency

Advantages of Panc02 Cells

The foremost advantage of Panc02 is its syngeneic compatibility with the C57BL/6 mouse strain. This means experiments can be performed in fully immunocompetent hosts, allowing researchers to study the genuine interplay between pancreatic tumour cells and the host immune system. Unlike xenograft models that require immunodeficient mice, the Panc02 system preserves T-cell responses, macrophage activity, and natural killer cell function — all of which are critically relevant to modern immunotherapy research. This feature has made Panc02 the model of choice for studying CD4-positive and CD8-positive T-lymphocyte dynamics in the pancreatic tumour microenvironment.

Panc02 is also highly versatile in terms of implantation routes. Researchers can employ subcutaneous, orthotopic, or intraperitoneal implantation depending on their experimental objectives. The orthotopic model, in which cells are injected directly into the pancreatic head, most faithfully recapitulates the anatomical and immunological context of human PDAC. [5] Additionally, the availability of engineered Panc02 derivatives — including luciferase-expressing lines such as Panc02-Luc Cells — enables non-invasive bioluminescence imaging of tumour growth and metastasis in live animals, greatly improving experimental throughput and reducing animal numbers.

From a practical standpoint, Panc02 is a robust and reliably growing adherent cell line with a well-characterised doubling time of approximately 61 hours. It responds reproducibly to a broad range of chemotherapeutic agents and immunomodulatory treatments, making it an excellent platform for comparative drug studies. The extensive published literature on Panc02 — spanning more than four decades — provides researchers with rich historical benchmarking data and validated experimental protocols, lowering the barrier to entry for new laboratories.

Limitations of Panc02 Cells

Despite its widespread use, Panc02 carries important biological caveats. The cell line was established through chemical carcinogenesis rather than through the stepwise accumulation of mutations typical of human PDAC. Human pancreatic ductal adenocarcinoma most commonly involves oncogenic KRAS mutations, CDKN2A inactivation, TP53 mutations, and SMAD4 loss. Genomic sequencing of Panc02 has revealed a divergent mutational landscape, which may limit direct extrapolation of drug response data to human patients. [2] Researchers should therefore interpret Panc02 results as hypothesis-generating rather than directly predictive of clinical outcomes.

A further limitation is the relatively moderate metastatic potential of parental Panc02 cells. In its baseline form, the line does not spontaneously metastasise efficiently, which can restrict its utility for studying advanced disease. Investigators seeking a highly metastatic model must either use serially passaged derivatives such as Panc02-H7 [4] or employ specialised in vivo selection approaches. The generation of such derivatives adds experimental complexity and may introduce additional phenotypic drift from the parental line.

Finally, as a murine cell line, Panc02 cannot fully recapitulate the genetic heterogeneity or stromal complexity of human pancreatic cancer. The murine tumour microenvironment, while immunocompetent, differs from its human counterpart in immune cell subset composition, cytokine milieu, and stromal architecture. Results from Panc02-based studies should therefore be validated in complementary human cell line models or patient-derived organoids before advancing candidate therapies toward clinical translation.

Applications

Syngeneic Orthotopic Models and Tumor Microenvironment Research

Panc02 is the cornerstone of syngeneic orthotopic PDAC modelling. Partecke and colleagues provided a landmark characterisation of this model in 2011, demonstrating that orthotopic injection of Panc02 into the pancreatic head of C57BL/6 mice produces tumours with local invasiveness and histological features consistent with pancreatic adenocarcinoma. [5] Crucially, the study showed that Panc02 tumours display an irregular, finger-like growth pattern — in contrast to the more spherical growth of 6606PDA cells — and that MRI can reliably monitor longitudinal tumour growth in this model. These findings established Panc02 as a clinically relevant immunocompetent platform for pancreatic cancer research.

The syngeneic orthotopic Panc02 model has since been applied extensively to study the immunosuppressive tumour microenvironment. Gnerlich and colleagues demonstrated that Panc02 tumours recruit regulatory T cells (Tregs) to suppress antitumour immunity, and that engineering Pan02 cells to secrete IL-6 promoted Th17 cell induction and improved survival in tumour-bearing mice. [6] This work highlighted the plasticity of the tumour immune microenvironment and the feasibility of cytokine-based manipulation strategies within this model.

More recently, Gao and colleagues exploited the Panc02 orthotopic model to evaluate complement-based immunotherapy. [7] By expressing membrane-anchored properdin on Panc02 cells, they amplified galactose-α-1,3-galactose-mediated complement activation and enhanced complement-dependent cytotoxicity. The model proved sensitive to this immune intervention, underscoring its value for dissecting innate immune pathways in the pancreatic tumour microenvironment. Park and colleagues further used a Panc02-transplanted murine model to investigate diabetes-related inflammation as a driver of pancreatic cancer progression, detecting circulating tumour cells via quantum dot-conjugated aptamers. [8]

Chemotherapy Resistance and Novel Drug Delivery Systems

Gemcitabine resistance is a defining clinical challenge in pancreatic cancer, and Panc02 has been extensively employed to investigate this problem and to evaluate novel therapeutic strategies. Takhsha and colleagues demonstrated in a syngeneic Panc02 mouse model that the ATG4B inhibitor UAMC-2526 significantly potentiated the chemotherapeutic effect of gemcitabine by suppressing autophagy in the hypoxic tumour microenvironment. [9] This study highlighted how autophagy inhibition can sensitise PDAC cells to standard chemotherapy, providing a rationale for combination regimens. Zhang and colleagues extended this concept by developing antibiotic-drug conjugates (Tob-SS-Gm nanoparticles) that covalently link tobramycin and gemcitabine via disulfide bonds, targeting intratumoral bacteria that express cytidine deaminase and thereby degrade gemcitabine. [10] Testing in Panc02 cells confirmed that conjugation preserved both antibacterial and chemotherapeutic activity, establishing a dual-function strategy against chemoresistance.

Nanoparticle-based drug delivery has emerged as a major application area for Panc02. Li and colleagues demonstrated that Lycium barbarum polysaccharide-stabilised selenium nanoparticles loaded with triptolide achieved significantly lower IC50 values in Pan02 cells compared with free triptolide, with sustained acid-dependent drug release. [11] Ge and colleagues developed RGD peptide/dextran sulfate nanocarriers for dual-targeted delivery of triptolide to both Pan02 tumour cells and M2-like tumour-associated macrophages, exploiting integrin αvβ3–RGD and SR-A–dextran sulfate interactions to achieve preferential tumour accumulation. [12] Together, these studies illustrate how Panc02 serves as a versatile in vitro and in vivo screening platform for nano-formulation optimisation.

Further drug delivery innovations tested in Panc02 include exosome-based triple-drug formulations and albumin nanoparticle systems. Zhang and colleagues loaded bone marrow mesenchymal stem cell-derived exosomes with galectin-9 siRNA, a gemcitabine prodrug, and indocyanine green, demonstrating enhanced apoptosis in pancreatic cancer cells with pH-dependent drug release. [13] Wen and colleagues developed polyallylamine hydrochloride-modified bovine serum albumin nanoparticles loaded with α-solanine, showing effective inhibition of Panc02 cell proliferation, migration, and invasion. [14] Kong and colleagues designed a CGT-Cls-PTX/CM nano-codelivery system using PANC02 cell membrane-derived antigens to co-deliver paclitaxel and tumour antigens, stimulating dendritic cell maturation and relieving immunosuppression. [15]

Immunotherapy and Immune Modulation

The immunocompetent nature of the Panc02 syngeneic model makes it uniquely suited to evaluating immunotherapeutic strategies. Hydroxytyrosol, a polyphenol derived from olive oil, was shown to inhibit Panc02 cell proliferation via the STAT3/Cyclin D1 signalling pathway in vitro, while in orthotopic tumour-bearing mice it suppressed tumour growth, reduced myeloid-derived suppressor cells (MDSCs), and increased M1 macrophage polarisation. [16] This study exemplified how Panc02 orthotopic models can simultaneously assess both direct cytotoxic effects and immunomodulatory mechanisms of candidate agents.

Microbiome-based immunotherapy has also been explored using Panc02 models. Li and colleagues conducted a detailed murine study using orthotopic Pan02 tumour implantation to evaluate fecal microbiota transplantation (FMT) combined with 5-fluorouracil, demonstrating that FMT modulated gut microbiota composition and enhanced systemic immune responses, improving antitumour efficacy. [17] Vruzhaj and colleagues tested engineered Escherichia coli Nissle 1917 as an oral delivery vector for glypican-1 in a PANC02-based immunotherapy model, confirming expression and stability of the GPC1-flagellin fusion protein in modified Panc02 cells as a step toward oral cancer vaccination. [18] These studies reflect growing interest in the gastrointestinal microbiome as a modulator of pancreatic cancer immunotherapy.

Oncolytic virotherapy represents another immunotherapeutic modality studied in the Panc02 context. Research comparing intertumoral heterogeneity across C57BL/6-background PDAC cell lines, including Panc02, demonstrated that oncolytic vesicular stomatitis virus efficacy varied markedly between syngeneic lines, with Panc02 serving as a reference point to contextualise differential viral susceptibility. This work underscored the importance of cellular heterogeneity when interpreting oncolytic virotherapy outcomes and informed the design of combination approaches to overcome tumour escape.

Metastasis and Tumor Progression Mechanisms

Panc02 has been instrumental in generating progressively metastatic derivatives to study the molecular basis of PDAC dissemination. Wang and colleagues established the Panc02-H7 lineage through iterative orthotopic implantation and isolation of liver micrometastases, creating a series of increasingly aggressive sublines culminating in Panc02-H7, which showed peritoneal dissemination and distant metastasis to liver and lungs. [4] This model provided one of the first clinically relevant platforms for studying haematogenous and peritoneal metastatic spread in an immunocompetent host.

More recently, Takahashi-Yamashiro and colleagues established highly metastatic Panc02-3P derivative cells through three serial orthotopic transplantation cycles. [19] RNA sequencing revealed mesenchymal-like gene expression changes in Panc02-3P cells compared with parental Panc02, implicating lysyl oxidase family members as novel molecular targets in PDAC progression — even in the absence of canonical EMT transcription factor changes. The role of epithelial-mesenchymal transition in Panc02 biology was further explored by Wang and colleagues, who showed that FV-429, a flavonoid derivative, suppressed migration and invasion of pancreatic cancer cells by modulating the Hippo/YAP1 pathway and EMT-related proteins. [20]

Perineural invasion — a hallmark of aggressive PDAC — has also been interrogated using Panc02. Hua and colleagues implanted Panc02-luc cells orthotopically to establish a perineural invasion model and demonstrated that Slc26a9 expression was markedly elevated in PNI-positive PDAC. [21] Mechanistic studies implicated Slc26a9 in promoting anxiety-like behaviours and mechanical hyperalgesia in tumour-bearing mice, linking tumour biology to clinically relevant pain phenotypes. Zhang and colleagues additionally used Panc02 subcutaneous and orthotopic liver metastasis models to elucidate the role of EMP1 — an aging-related factor — in accelerating pancreatic cancer progression, demonstrating that EMP1 overexpression enhanced tumour growth and metastasis. [22]

Photodynamic and Physical Ablation Therapies

Panc02 cells have served as a relevant test system for photodynamic therapy (PDT) and physical ablation modalities. Xu and colleagues synthesised a panel of organelle-targeted photosensitisers based on pyropheophorbide a, evaluating mitochondria-, lysosome-, endoplasmic reticulum-, and nucleus-targeted variants for their ability to concentrate reactive oxygen species at critical subcellular sites and enhance PDT efficacy, with testing performed across multiple cancer cell lines including Panc02. [23] This systematic comparison provided mechanistic insight into organelle targeting as a strategy to overcome the limitations of conventional photosensitisers.

Wang and colleagues evaluated the combination of low-frequency ultrasound-stimulated microbubbles (USMB) and radiofrequency ablation (RFA) in Panc02 cells and subcutaneous xenograft mice. [24] CCK-8 assays showed significant suppression of Panc02 cell proliferation with the combination treatment, and tumour-bearing mice exhibited improved survival and modulation of immune-related and apoptosis-related factors. This study demonstrated the potential of combining physical ablation modalities with sonodynamic perturbation of the tumour microenvironment, a concept uniquely testable in the immunocompetent Panc02 model.

Conclusion

Panc02 (CVCL_D627) occupies a central position in pancreatic cancer research as a syngeneic, immunocompetent murine model of pancreatic ductal adenocarcinoma. From its establishment through chemical carcinogenesis in C57BL/6 mice in 1984 [1] to its current deployment across drug delivery nanotechnology, tumour microenvironment immunology, oncolytic virotherapy, and metastasis biology, the cell line has demonstrated remarkable scientific longevity. Its orthotopic implantation characteristics — well-documented by Partecke and colleagues [5] — and its compatibility with modern bioluminescence imaging make it a versatile and rigorous platform for preclinical evaluation of novel therapies for pancreatic neoplasms. Whether your laboratory is investigating carcinoma of the pancreatic ductal type, exploring the gastrointestinal microbiome's role in treatment response, or developing next-generation nanoparticle delivery systems, Panc02 provides a scientifically validated foundation. Visit cytion.com to explore full product specifications or to purchase Panc02 cells for your research.

Key Publications

1. Corbett TH, Roberts BJ, Leopold WR (1984) Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Research. PMID: 6692374
2. Wang Y, Zhang Y, Yang J (2012) Genomic sequencing of key genes in mouse pancreatic cancer cells. Current Molecular Medicine. PMID: 22208613
3. Torres MP, Rachagani S, Souchek JJ (2013) Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy. PloS One. PMID: 24278292
4. Wang B, Shi Q, Abbruzzese JL (2001) A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy. International Journal of Pancreatology. PMID: 11558631
5. Partecke LI, Sendler M, Kaeding A (2011) A syngeneic orthotopic murine model of pancreatic adenocarcinoma in the C57/BL6 mouse using the Panc02 and 6606PDA cell lines. European Surgical Research. PMID: 21720167
6. Gnerlich JL, Mitchem JB, Weir JS (2010) Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. Journal of Immunology. PMID: 20805420
7. Gao M, Kechagia S, Ramachandran M (2026) Shaping Tumor Microenvironment by Amplifying the Complement Cascade for Improved Immune Response in Pancreatic Cancer Model. Molecular Cancer Therapeutics. PMID: 41159389
8. Park Y, Kim ST, Kim YM (2025) Role of diabetes-related inflammation in pancreatic cancer evaluated by aptamer-based detection of circulating tumor cells in a streptozotocin-induced Panc02-transplanted murine model. Annals of Hepato-Biliary-Pancreatic Surgery. PMID: 40759530
9. Takhsha FS, Vangestel C, Tanc M (2021) ATG4B Inhibitor UAMC-2526 Potentiates the Chemotherapeutic Effect of Gemcitabine in a Panc02 Mouse Model of Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology. PMID: 34868951
10. Zhang Z, Zhang F, Yang W (2026) Antibiotic-drug conjugates: Enhancing chemo-immunotherapy of gemcitabine for pancreatic cancer by eliminating intratumoral bacteria. Biomaterials. PMID: 42302584
11. Li X, Su Y, Lin N (2025) Lycium barbarum Polysaccharide-Stabilized Selenium Nanoparticles Deliver Triptolide to Induce Apoptosis for Pancreatic Cancer In Vitro and In Vivo. ACS Omega. PMID: 40352487
12. Ge Y, Zhu X, Zhang Z (2025) RGD peptide/dextran sulfate-based nanocarriers loaded with triptolide for double-targeted apoptosis of both tumor cells and M2-like TAMs in pancreatic cancer therapy. International Journal of Biological Macromolecules. PMID: 40345287
13. Zhang R, Zhang Y, Hao F (2025) Exosome-mediated triple drug delivery enhances apoptosis in pancreatic cancer cells. Apoptosis: An International Journal on Programmed Cell Death. PMID: 40488835
14. Wen Z, Luo S, Liu J (2025) Polyallylamine Hydrochloride-Modified Bovine Serum Albumin Nanoparticles Loaded with α-Solanine for Chemotherapy of Pancreatic Cancer. International Journal of Nanomedicine. PMID: 40225222
15. Kong Y, Zhao J, Xu B (2026) Construction and synergistic effect of a CGT-Cls-PTX/CM nanocodelivery system targeting the tumor microenvironment. Nanotechnology. PMID: 41554179
16. Wang B, Yang L, Liu T (2021) Hydroxytyrosol Inhibits MDSCs and Promotes M1 Macrophages in Mice With Orthotopic Pancreatic Tumor. Frontiers in Pharmacology. PMID: 34858184
17. Li R, Hu Y, Liu Y (2025) Fecal microbiota transplantation augments 5-fluorouracil efficacy in pancreatic cancer via gut microbiota modulation. Frontiers in Microbiology. PMID: 41078530
18. Vruzhaj I, Gambirasi M, Busato D (2025) Gut Microbiota-Based Immunotherapy: Engineered Escherichia coli Nissle 1917 for Oral Delivery of Glypican-1 in Pancreatic Cancer. Medicina (Kaunas, Lithuania). PMID: 40282924
19. Takahashi-Yamashiro K, Miyauchi K, Shimomura K (2026) In vitro functional analysis of lysyl oxidase family members in highly metastatic pancreatic cancer cells derived from a syngeneic orthotopic model. BMC Cancer. PMID: 42298507
20. Wang Z, Pan X, Ma X (2025) FV-429 suppresses cancer cell migration and invasion by EMT via the Hippo/YAP1 pathway in pancreatic cancer cells. Anti-Cancer Drugs. PMID: 40071582
21. Hua B, Huang X, Chen L (2025) Slc26a9 promotes the perineural invasion of pancreatic cancer in mice. Biochemical and Biophysical Research Communications. PMID: 41232379
22. Zhang J, Gu J, Zhang T (2025) The role of the aging process and related factor EMP1 in promoting progression of resectable pancreatic cancer. Genes & Diseases. PMID: 40612666
23. Xu Y, Zeng W, Liu R (2026) Organelle-Targeted Photosensitizers for Enhanced Photodynamic Therapy of Cancer. Bioconjugate Chemistry. PMID: 42186767
24. Wang H, Ding W, Shi H (2021) Combination therapy with low-frequency ultrasound irradiation and radiofrequency ablation as a synergistic treatment for pancreatic cancer. Bioengineered. PMID: 34696663